CWRU and UTMC-linked Rodeo Therapeutics is set to be acquired by Amgen for $55m in upfront and up to $666m in milestone payments.

Rodeo Therapeutics, a US-based small-molecule therapy developer based on research at Case Western Reserve University and University of Texas Southwestern Medical Center, has agreed to an acquisition by pharmaceutical firm Amgen for up to $721m. Amgen will pay an initial $55m and up to $666m in cash subject to milestones. Rodeo is developing small-molecule therapies, including its…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.